Two more at-home tests win FDA approval To view this email as a web page,
click here Merck, Johnson & Johnson to strike 'wartime' COVID-19 vaccine manufacturing deal: WaPo Congress to investigate One Medical's vaccination practices: report FDA greenlights home COVID-19 testing kits from Quidel, Eurofins Novavax targets May approval for COVID-19 vaccine in the U.S. COVID-19 tracker: Supply-starved EU countries look elsewhere for vaccines AMA, ANA call for improved efforts to collect race, ethnicity data on COVID-19 vaccinations Blue Cross NC saw $200M in COVID-related claims last year Little Cerecor sees shares jump on COVID-19 readout, seeks EUA though margins of success are thin Featured Story | By Eric Sagonowsky Merck & Co., a leading vaccine player worldwide, has been largely absent during the COVID-19 vaccine race. Not anymore: The drugmaker is set to partner with Johnson & Johnson to boost production of its newly authorized shot, The Washington Post reports. read more |
| |
|---|
|
Top Stories By Heather Landi Congress is launching an investigation into concierge healthcare provider One Medical following allegations that the company has been administering COVID-19 vaccinations to ineligible patients. read more By Conor Hale After one year and hundreds of individual diagnostic authorizations for COVID-19, the FDA is now greenlighting more tests that can be performed or started at home, and on a much broader scale. read more By Nick Paul Taylor Novavax is targeting a second-quarter FDA filing for emergency use of its COVID-19 vaccine. The goal suggests the U.S. could join the U.K. on the list of countries to authorize the vaccine in the first half of the year. read more By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale The EU is showing cracks as some supply-starved countries are going outside the bloc to secure COVID-19 vaccines. Johnson & Johnson has teamed with Merck & Co. in a "wartime" alliance to supply vaccines. The FDA has endorsed at-home COVID-19 testing kits from Quidel and Eurofins. Promising results emerge for Cerecor's antibody med. read more By Heather Landi Major healthcare groups are calling for the industry to redouble efforts to collect and report race and ethnicity data when administering COVID-19 vaccinations. read more By Paige Minemyer Blue Cross and Blue Shield of North Carolina saw $200 million in claims related to COVID-19 last year, the insurer said during a briefing Tuesday. read more By Ben Adams Cerecor, which has a market cap of less than $400 million and some small, low-key raises and pacts over the years, saw its shares bounce around 15% premarket this morning on new phase 2 data for its experimental COVID-19 drug. read more |
|
